Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

(2021) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

37 FECAL MICROBIOTA TRANSPLANATION IS HIGHLY EFFECTIVE IN REAL-WORLD PRACTICE: INITIAL RESULTS FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION FECAL MICROBIOTA TRANSPLANTATION NATIONAL REGISTRY

(2020) Colleen R. Kelly et al.   GASTROENTEROLOGY

Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes

(2020) Alice Y. Guh et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis

(2020) Mark H Wilcox et al.   Open Forum Infectious Diseases

Shiga toxin-producing E. coli transmission via fecal microbiota transplant

(2020) Caroline Zellmer et al.   CLINICAL INFECTIOUS DISEASES

Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of Rbx2660—An Investigational Microbiome Restoration Therapeutic

(2019) Ken F Blount et al.   Open Forum Infectious Diseases

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant

(2019) Zachariah DeFilipp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

(2018) Erik R Dubberke et al.   CLINICAL INFECTIOUS DISEASES

Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis

(2018) Raseen Tariq et al.   CLINICAL INFECTIOUS DISEASES

RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent Clostridium difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results

(2017) Robert Orenstein et al.   Open Forum Infectious Diseases

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection

(2016) Sahil Khanna et al.   JOURNAL OF INFECTIOUS DISEASES

Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation

(2016) Christopher Staley et al.   mBio

Fecal Microbiota Transplantation forClostridium difficileInfection

(2015) Dimitri Drekonja et al.   ANNALS OF INTERNAL MEDICINE

Clinical and Healthcare Burden of Multiple Recurrences ofClostridium difficileInfection

(2015) Caroline Sheitoyan-Pesant et al.   CLINICAL INFECTIOUS DISEASES

Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study

(2015) Robert Orenstein et al.   CLINICAL INFECTIOUS DISEASES

Recurrent Clostridium difficile infection is associated with increased mortality

(2015) M.A. Olsen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Recovery of the Gut Microbiome following Fecal Microbiota Transplantation

(2014) A. M. Seekatz et al.   mBio

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Hypothesis Testing and Power Calculations for Taxonomic-Based Human Microbiome Data

(2012) Patricio S. La Rosa et al.   PLoS One